High percentage of ADAM-10 positive melanoma cells correlates with paucity of tumor-infiltrating lymphocytes but does not predict prognosis in cutaneous melanoma patients.
ADAM-10 (CDw156, CD156c, and kuzbanian) is a protein belonging to a superfamily of metalloproteases, enzymes capable of degrading the extracellular matrix. ADAMs have also been shown to be primarily involved in ectodomain cleavage. The aim of the study was to assess the expression and intracellular location of ADAM-10 in 104 primary skin melanomas and 16 metastatic lesions from regional lymph nodes. Also, prognostic significance of ADAM-10 expression in primary tumor cells and metastatic lesion cells was evaluated during 5-year observation. It was revealed that high expression of ADAM-10 positive cells was strictly related with lower intensity of tumor-infiltrating lymphocytes (P = 0.037), which suggests that ADAM-10 regulates immunoresponse in melanoma initiation and progression. No statistically significant correlations were found between ADAM-10 expression in primary tumor cells and nodal metastases and other histopathological parameters analyzed. Decreased immunoreactivity of ADAM-10 in cancer cells from regional lymph nodes was correlated with worse prognosis; however this correlation was statistically nonsignificant (P = 0.065). Review of the literature shows that our study is the first one ever to describe the significance of ADAM-10 expression in correlation with detailed histopathological parameters of the primary tumor and data on long-term survival of cutaneous melanoma patients.
Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland.
Piotr
P
Donizy
Lower Silesian Oncology Centre, pl. Hirszfelda 12, 53-413 Wroclaw, Poland.
Marcin
M
Zietek
Department of Statistics, Wroclaw University of Economics, Komandorska 118-120, 53-345 Wroclaw, Poland.
Marek
M
Leskiewicz
Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland.
Agnieszka
A
Halon
Lower Silesian Oncology Centre, pl. Hirszfelda 12, 53-413 Wroclaw, Poland ; Department of Oncology and Division of Surgical Oncology, Wroclaw Medical University, pl. Hirszfelda 12, 53-413 Wroclaw, Poland.
Rafal
R
Matkowski
D051722:ADAM Proteins / Q000378:metabolism*; D000072197:ADAM10 Protein; D000328:Adult; D000368:Aged; D053829:Amyloid Precursor Protein Secretases / Q000378:metabolism*; D015820:Cadherins / Q000378:metabolism; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D016246:Lymphocytes, Tumor-Infiltrating / Q000473:pathology*; D008297:Male; D008545:Melanoma / Q000378:metabolism / Q000473:pathology*; D008565:Membrane Proteins / Q000378:metabolism*; D008875:Middle Aged; D015676:Osteonectin / Q000378:metabolism; D011379:Prognosis; D012878:Skin Neoplasms / Q000378:metabolism / Q000473:pathology*; D016019:Survival Analysis; D055815:Young Adult; D000096142:Cutaneous Malignant Melanoma
D015820:Cadherins; D008565:Membrane Proteins; D015676:Osteonectin; D053829:Amyloid Precursor Protein Secretases; D051722:ADAM Proteins; D000072197:ADAM10 Protein; C491236:ADAM10 protein, human